Geneos Wealth Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $387K | Hold |
3,030
| – | – | 0.01% | 769 |
|
|
2025
Q4 | $369K | Buy |
3,030
+650
| +27% | +$74.5K | 0.01% | 751 |
|
|
2025
Q3 | $238K | Hold |
2,380
| – | – | 0.01% | 848 |
|
|
2025
Q2 | $197K | Sell |
2,380
-1,282
| -35% | -$102K | ﹤0.01% | 1002 |
|
|
2025
Q1 | $297K | Buy |
3,662
+2,471
| +207% | +$221K | ﹤0.01% | 1081 |
|
|
2024
Q4 | $107K | Sell |
1,191
-300
| -20% | -$29.1K | ﹤0.01% | 1046 |
|
|
2024
Q3 | $147K | Sell |
1,491
-50
| -3% | -$4.91K | 0.01% | 856 |
|
|
2024
Q2 | $143K | Hold |
1,541
| – | – | 0.01% | 786 |
|
|
2024
Q1 | $146K | Buy |
1,541
+145
| +10% | +$13.5K | 0.01% | 769 |
|
|
2023
Q4 | $125K | Sell |
1,396
-40
| -3% | -$2.97K | 0.01% | 780 |
|
|
2023
Q3 | $105K | Sell |
1,436
-350
| -20% | -$28K | 0.01% | 862 |
|
|
2023
Q2 | $149K | Sell |
1,786
-350
| -16% | -$29.3K | 0.01% | 758 |
|
|
2023
Q1 | $163K | Buy |
2,136
+12
| +0.6% | +$996 | 0.01% | 704 |
|
|
2022
Q4 | $176K | Hold |
2,124
| – | – | 0.01% | 664 |
|
|
2022
Q3 | $168K | Sell |
2,124
-1,150
| -35% | -$97K | 0.01% | 649 |
|
|
2022
Q2 | $250K | Buy |
3,274
+245
| +8% | +$18.4K | 0.01% | 671 |
|
|
2022
Q1 | $272K | Sell |
3,029
-2,750
| -48% | -$254K | 0.01% | 696 |
|
|
2021
Q4 | $647K | Sell |
5,779
-172
| -3% | -$20.7K | 0.02% | 505 |
|
|
2021
Q3 | $750K | Sell |
5,951
-300
| -5% | -$38.6K | 0.03% | 468 |
|
|
2021
Q2 | $853K | Sell |
6,251
-2,536
| -29% | -$333K | 0.03% | 410 |
|
|
2021
Q1 | $1.2M | Buy |
8,787
+304
| +4% | +$45.5K | 0.03% | 378 |
|
|
2020
Q4 | $874K | Buy |
8,483
+867
| +11% | +$111K | 0.04% | 387 |
|
|
2020
Q3 | $843K | Buy |
7,616
+31
| +0.4% | +$3.48K | 0.04% | 322 |
|
|
2020
Q2 | $837K | Buy |
7,585
+55
| +0.7% | +$5.42K | 0.05% | 311 |
|
|
2020
Q1 | $571K | Buy |
7,530
+456
| +6% | +$40.4K | 0.04% | 356 |
|
|
2019
Q4 | $680K | Sell |
7,074
-1,324
| -16% | -$115K | 0.04% | 380 |
|
|
2019
Q3 | $642K | Sell |
8,398
-632
| -7% | -$52.5K | 0.04% | 358 |
|
|
2019
Q2 | $792K | Buy |
9,030
+658
| +8% | +$56.1K | 0.05% | 318 |
|
|
2019
Q1 | $758K | Buy |
8,372
+1,124
| +16% | +$95.6K | 0.05% | 320 |
|
|
2018
Q4 | $508K | Sell |
7,248
-191
| -3% | -$15.4K | 0.04% | 369 |
|
|
2018
Q3 | $713K | Buy |
7,439
+439
| +6% | +$42.6K | 0.05% | 318 |
|
|
2018
Q2 | $666K | Hold |
7,000
| – | – | 0.05% | 279 |
|
|
2018
Q1 | $614K | Buy |
7,000
+511
| +8% | +$46.7K | 0.05% | 272 |
|
|
2017
Q4 | $550K | Sell |
6,489
-695
| -10% | -$58.2K | 0.05% | 297 |
|
|
2017
Q3 | $621K | Buy |
7,184
+237
| +3% | +$19K | 0.06% | 265 |
|
|
2017
Q2 | $536K | Buy |
6,947
+50
| +0.7% | +$3.55K | 0.06% | 278 |
|
|
2017
Q1 | $478K | Buy |
6,897
+600
| +10% | +$40.3K | 0.05% | 287 |
|
|
2016
Q4 | $372K | Buy |
6,297
+1,306
| +26% | +$80.6K | 0.05% | 315 |
|
|
2016
Q3 | $330K | Buy |
4,991
+86
| +2% | +$5.32K | 0.04% | 335 |
|
|
2016
Q2 | $273K | Sell |
4,905
-173
| -3% | -$9.48K | 0.04% | 368 |
|
|
2016
Q1 | $269K | Buy |
+5,078
| New | +$264K | 0.04% | 363 |
|
Other funds holding XBI
Geneos Wealth Management's XBI Position: Q1 2026 in Review
Geneos Wealth Management held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q1 2026 at 3,030 shares worth $387K. The position accounts for 0.01% of the portfolio, ranked #769.
Geneos Wealth Management first reported a position in XBI in Q1 2016 and has held it in 41 quarters since. The position peaked at $1.2M in Q1 2021. 813 funds tracked by Wall St. Rank hold XBI as of Q1 2026.
- Geneos Wealth Management held 3,030 shares of State Street SPDR S&P Biotech ETF worth $387K as of Q1 2026.
- Geneos Wealth Management left its State Street SPDR S&P Biotech ETF share count unchanged in Q1 2026.
- State Street SPDR S&P Biotech ETF made up 0.01% of Geneos Wealth Management's portfolio in Q1 2026, its #769 holding.
- Geneos Wealth Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2016 and has held it in 41 quarters since.
- Geneos Wealth Management's State Street SPDR S&P Biotech ETF position peaked at $1.2M in Q1 2021.
- 813 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.
Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.